论文部分内容阅读
目的：考察及确认重组白细胞介素-2（IL-2）腔内灌注并全身化疗对癌性胸腔积液的疗效及IL－2介入治疗的毒副作用。方法：观察48例经病理确诊的癌性胸水患者，随机分为治疗组与对照组各24例，治疗组在尽量抽去胸水后胸腔内灌注IL－240－60万u／m2体表面积，每周1－2次，连续4周，同时进行全身化疗，对照组仅给单纯化疗，两组给予同一化疗方案。结果：按WHO规定的癌性渗液评定标准进行疗效评定，治疗组完全缓解（CR）13例，部分缓解（PR）8例，总缓解率（CR）＋（PR）87．5％（21／24），显著高于对照组58．33％（14／24，P＜0．01），毒副反应主要表现为发热、畏寒。结论：IL－2治疗癌性胸水疗效肯定，合并化疗效果更佳，值得推广。
Objective: To investigate and confirm the efficacy of intraluminal infusion of recombinant interleukin-2 (IL-2) and systemic chemotherapy for cancerous pleural effusion and the toxic side effects of interleukin-2 intervention. Methods: Forty-eight cases of cancerous pleural effusions diagnosed by pathology were randomly divided into treatment group and control group with 24 cases. The treatment group was treated with pleural effusion after perfusion of IL-240-600,000 u/m2 body surface area. Weeks 1-2 times, for 4 weeks, systemic chemotherapy was performed at the same time. The control group was given only chemotherapy, and the two groups were given the same chemotherapy. Results: According to the evaluation criteria of cancerous exudate specified by WHO, 13 patients were completely relieved (CR), 8 patients were partially relieved (PR), and the total remission rate (CR) + (PR) was 87.5% (21 /24), significantly higher than the control group 58.33% (14/24, P <0.01), toxic side effects are mainly fever, chills. Conclusion: The efficacy of IL-2 in the treatment of malignant pleural effusion is positive, and the effect of combined chemotherapy is better. It is worth promoting.